Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 139

Sort by

Sort Order Select

Journal Articles

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

Takashi Ishio, Joji Shimono, Sarvesh Kumar, Yuquan Lin, Emmanuel Bachy, Michael N. Petrus, Yandan Yang, Michiyuki Maeda, Hideki Goto, Satoshi Hashino, Takanori Teshima, MD, Thomas A. Waldmann, MD, Louis Staudt, MD, Masao Nakagawa

Blood (2019) 134 (Supplement_1): 3781.

https://doi.org/10.1182/blood-2019-124670

Published: 2019

Journal Articles

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

Kazuharu Kamachi, MD, Hiroshi Ureshino, MD, Nao Yoshida, MD, Yuki Kurahashi, Tatsuro Watanabe, PhD, Seiji Okada, MD PhD, Shinya Kimura, MD PhD

Blood (2019) 134 (Supplement_1): 5365.

https://doi.org/10.1182/blood-2019-125460

Published: 2019

Journal Articles

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

Juan J. Gu, MD PhD, Samuel J. Thompson, Cory Mavis, MSc, Matthew J. Barth, MD, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 5301.

https://doi.org/10.1182/blood-2019-129009

Published: 2019

Journal Articles

HO-1 Promotes Resistance to EZH2 Inhibitor through the Prb-E2F Pathway: Corelated with the Conversion of Myelodysplastic Syndrome to Acute Myeloid Leukemia

Zhengchang He, Jishi Wang, PhD

Blood (2019) 134 (Supplement_1): 5401.

https://doi.org/10.1182/blood-2019-131573

Published: 2019

Journal Articles

CDK6 Antagonizes TP53-Induced Responses during Tumorigenesis

Veronika Sexl, MD PhD, Karoline Kollmann, PhD, Florian Bellutti

Blood (2019) 134 (Supplement_1): SCI-15.

https://doi.org/10.1182/blood-2019-121101

Published: 2019

Journal Articles

Overcoming Drug Resistance in Myeloma By Synchronized Delivery of Therapeutic and Bone Marrow Disrupting Agents By Nanoparticles Targeting Tumor-Associated Endothelium

Cinzia Federico, PhD, Barbara Muz, PhDMSc, Jennifer Sun, BSc, Kinan Alhallak, BSc, Justin King, Daniel R. Kohnen, MBA, Mark A. Fiala, BS, Aldo M. Roccaro, MDPhD, Ravi Vij, MBBS, Abdel Kareem Azab, PhD

Blood (2018) 132 (Supplement 1): 1931.

https://doi.org/10.1182/blood-2018-99-118251

Published: 2018

Journal Articles

UBR5 Mutations in Mantle Cell Lymphoma Lead to Increased Proliferation through a Cyclin D1-Dependent Mechanism

Olga Kutovaya, PhD, Stacy Hung, Elena Viganò, PhD, Adele Telenius, Bruce W Woolcock, Barbara Meissner, PhD, Shane Colborne, BSc, Randy D. Gascoyne, MD, Diego Villa, MD, Ryan D. Morin, PhD, BSc, MSc, David W. Scott, PhD MD, FRACP, FRCPA, Gregg B Morin, PhD, Christian Steidl, MD

Blood (2018) 132 (Supplement 1): 2849.

https://doi.org/10.1182/blood-2018-99-118524

Published: 2018

Journal Articles

Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group

Yannick LE Bris, MDPharmD, Danielle Canioni, MD, Barbara Burroni, MD, Anne Moreau, MD, Benoit Tessoulin, MD, Florence Magrangeas, PhD, Marie-Helene Delfau, MD, Catherine Thieblemont, MD, Lucie Oberic, MD, Krimo Bouabdallah, MD, Emmanuel Gyan, MD PhD, David Chiron, PhD, Catherine Pellat-deceunynck, PhD, Mary Callanan, PhD, Stephane Minvielle, PhD, Marie C Bene, PharmSci, PhD, Olivier Hermine, MD PhD, Steven Le Gouill, MD PhD

Blood (2018) 132 (Supplement 1): 2846.

https://doi.org/10.1182/blood-2018-99-113268

Published: 2018

Journal Articles

Targeting Distinct Promoter- and Enhancer-Driven Dependencies in Multiple Myeloma

Chandraditya Chakraborty, PhD, Mehmet Kemal Samur, PhD, Richard A. Young, PhD, Kenneth Anderson, MD, Charles Y Lin, PhD, Mariateresa Fulciniti, PhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 3156.

https://doi.org/10.1182/blood-2018-99-112583

Published: 2018

Journal Articles

E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients

Alessandro Lagana, PhD, Seongjee Park, Donna Edwards, Violetta Leshchenko, PhD, Marsha Crochiere, Yosef Landesman, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Deepak Perumal, PhD, Deepu Madduri, MD, Joshua Richter, Ajai Chari, MD, Hearn Jay Cho, MD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2018) 132 (Supplement 1): 3216.

https://doi.org/10.1182/blood-2018-99-116500

Published: 2018

Journal Articles

Characterization of RB1 in Pediatric TCF3-PBX1+ acute Lymphoblastic Leukemia

Thayana da Conceição Barbosa, MSc, Marcela Braga Mansur, MsC, PhD, Caroline Barbieri Blunck, MsC, Mariana Emerenciano, MsC, PhD, Maria S. Pombo-de-Oliveira, MD PhD

Blood (2017) 130 (Supplement 1): 3976.

https://doi.org/10.1182/blood.V130.Suppl_1.3976.3976

Published: 2017

Journal Articles

Predicting Response to CDK4/6 Inhibitors and Combinations Using a Computational Biology Model and Its Validation: A Beat AML Project Study

Leylah M. Drusbosky, PhD, Madeleine Turcotte, MS, Paul Castillo, MD, Robinson Vidva, BT, Saji Gera, MT, Mohammed Sauban, BE, Priyanka Bhargav, BE, Punya Deep, MS, Shweta Kapoor, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 3909.

https://doi.org/10.1182/blood.V130.Suppl_1.3909.3909

Published: 2017

Journal Articles

Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Rita Assi, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Tapan Kadia, MD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Nitin Jain, MD, Naval Daver, MD, Taisuke Uehara, Takashi Owa, PhD, Gautam Borthakur, MD

Blood (2017) 130 (Supplement 1): 1380.

https://doi.org/10.1182/blood.V130.Suppl_1.1380.1380

Published: 2017

Journal Articles

Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells

Baohua Sun, MD PhD, Warren Fiskus, BSc,PhD, Kanak Raina, PhD, Yimin Qian, PhD, Andrew Crew, Dyana T. Saenz, PhD, Christopher Peter Mill, PhD BA, Agnieszka J Nowak, David N Saenz, Craig M Crews, PhD, Kapil N. Bhalla, MD

Blood (2017) 130 (Supplement 1): 1265.

https://doi.org/10.1182/blood.V130.Suppl_1.1265.1265

Published: 2017

Journal Articles

An Evaluation of the Cytotoxic Effect of the Natural Product Aaptamine Against t(4;11) Leukemias

Chandrima Sinha, PhD, John Bowling, PhD, Aman Seth, MS, Bensheng Ju, PhD, Bhaskar Kahali, PhD, Mark Hamann, PhD, Lea C. Cunningham, MD

Blood (2016) 128 (22): 1624.

https://doi.org/10.1182/blood.V128.22.1624.1624

Published: 2016

Journal Articles

Molecular Mechanism behind the Synergistic Activity of Proteasome Inhibition and PRC2 Inhibition in the Treatment of Multiple Myeloma

Ola Rizq, MD, Naoya Mimura, MD PhD, Motohiko Oshima, PhD, Atsunori Saraya, Shuhei Koide, PhD, Yuko Kato, PhD, Kazumasa Aoyama, PhD, Yaeko Nakajima-Takagi, PhD, Changshan Wang, PhD, Anqi Ma, Jian Jin, PhD, Tohru Iseki, MD PhD, Chiaki Nakaseko, MD, PhD, Atsushi Iwama, MD PhD

Blood (2016) 128 (22): 312.

https://doi.org/10.1182/blood.V128.22.312.312

Published: 2016

Journal Articles

Efficacy of Selinexor Is Dependent on IκB-α Expression and NF-Kb Deactivation in Multiple Myeloma Cells

Trinayan Kashyap, MS, Boris Klebanov, MA, MS, Christian Argueta, PhD, Margaret S. Lee, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD PhD, Yosef Landesman, PhD, William Senapedis, PhD

Blood (2016) 128 (22): 5660.

https://doi.org/10.1182/blood.V128.22.5660.5660

Published: 2016

Journal Articles

EZH2 Enables the Proliferation of Germinal Center B Cells and DLBCL through a Rb-E2F1 Positive Feedback Loop Involving Repression of CDKN1A

Wendy Béguelin, PhD, Martin A Rivas, PhD, María Teresa Calvo Fernández, Ari Melnick, MD

Blood (2016) 128 (22): 734.

https://doi.org/10.1182/blood.V128.22.734.734

Published: 2016

Journal Articles

Rituximab-Induced CD20-Mediated Signals and Suppression of PI3K-AKT Pathway Cooperates to Inhibit B-Cell Lymphoma Growth By Down-Regulation of Myc.

Tsuyoshi Nakamaki, MD, Yuta Baba, MD, Maasa Abe, MD, Sou Murai, MD, Megumi Watanuki, MD, Nobuyuki Kabasawa, MD, Kouji Yanagisawa, MD, Norimichi Hattori, MD, Yukiko Kawaguchi, MD, Nana Arai, MD, Shun Fujiwara, MD, Bungo Saito, MD

Blood (2016) 128 (22): 5312.

https://doi.org/10.1182/blood.V128.22.5312.5312

Published: 2016

Journal Articles

Anti-CD38 Targeted Nanoparticles for Drug Delivery in Multiple Myeloma

Pilar De La Puente, PhD, Abbey Jin, Micah John Luderer, BS, MS, Barbara Muz, PhD MSc, Justin A King, Ravi Vij, MD MBA, Abdel Kareem Azab, BPharm, PhD

Blood (2016) 128 (22): 2135.

https://doi.org/10.1182/blood.V128.22.2135.2135

Published: 2016

NARROW

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

HO-1 Promotes Resistance to EZH2 Inhibitor through the Prb-E2F Pathway: Corelated with the Conversion of Myelodysplastic Syndrome to Acute Myeloid Leukemia

CDK6 Antagonizes TP53-Induced Responses during Tumorigenesis

Overcoming Drug Resistance in Myeloma By Synchronized Delivery of Therapeutic and Bone Marrow Disrupting Agents By Nanoparticles Targeting Tumor-Associated Endothelium

UBR5 Mutations in Mantle Cell Lymphoma Lead to Increased Proliferation through a Cyclin D1-Dependent Mechanism

Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group

Targeting Distinct Promoter- and Enhancer-Driven Dependencies in Multiple Myeloma

E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients

Characterization of RB1 in Pediatric TCF3-PBX1+ acute Lymphoblastic Leukemia

Predicting Response to CDK4/6 Inhibitors and Combinations Using a Computational Biology Model and Its Validation: A Beat AML Project Study

Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells

An Evaluation of the Cytotoxic Effect of the Natural Product Aaptamine Against t(4;11) Leukemias

Molecular Mechanism behind the Synergistic Activity of Proteasome Inhibition and PRC2 Inhibition in the Treatment of Multiple Myeloma

Efficacy of Selinexor Is Dependent on IκB-α Expression and NF-Kb Deactivation in Multiple Myeloma Cells

EZH2 Enables the Proliferation of Germinal Center B Cells and DLBCL through a Rb-E2F1 Positive Feedback Loop Involving Repression of CDKN1A

Rituximab-Induced CD20-Mediated Signals and Suppression of PI3K-AKT Pathway Cooperates to Inhibit B-Cell Lymphoma Growth By Down-Regulation of Myc.

Anti-CD38 Targeted Nanoparticles for Drug Delivery in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only